Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Arcoxia/Cardiome Oxyprim for gout

Executive Summary

FDA's Arthritis Advisory Committee will discuss NDAs for Merck's Arcoxia for acute gout and Cardiome's Oxyprim in the treatment of gout at its June 2-3 meeting. On June 2, the committee will consider Oxyprim and trial design/endpoints for chronic gout. Arcoxia will be discussed on June 3 in conjunction with trial endpoints and design for acute gout. The topic was previously scheduled for discussion on Nov. 13, 2003, but the meeting was postponed. The meeting will be held at CDER's advisory committee conference room at 5630 Fishers Lane in Rockville, Md. at 8 a.m...

You may also be interested in...

Oxyprim Gout Therapy To Be Limited To Allopurinol Failures, Cardiome Says

Cardiome's risk management plan for the chronic gout therapy Oxyprim would require proof of patient failure on standard therapy before administration, Exec VP-Clinical Development Alan Moore, PhD, said June 2

QUOTED. 19 February 2020. Stephen Hahn.

The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts